Journal
NUCLEIC ACIDS RESEARCH
Volume 47, Issue 15, Pages 7753-7766Publisher
OXFORD UNIV PRESS
DOI: 10.1093/nar/gkz638
Keywords
-
Categories
Funding
- German Federal Ministry of Education and Research (BMBF) [eBio:MelEVIR 031L0073A]
- Staedler Stiftung [ww/eh 30/16]
- Cancer Institute of NSW Fellowship
- ELAN-fund of Universit atsklinikum Erlangen [16-08-16-1-Lai]
- Deutsche Forschungsgemeinschaft
- Friedrich-Alexander-Universitat Erlangen-Nurnberg
Ask authors/readers for more resources
MicroRNAs (miRNAs) are short, noncoding RNAs that regulate gene expression by suppressing mRNA translation and reducing mRNA stability. A miRNA can potentially bind many mRNAs, thereby affecting the expression of oncogenes and tumor suppressor genes as well as the activity of whole pathways. The promise of miRNA therapeutics in cancer is to harness this evolutionarily conserved mechanism for the coordinated regulation of gene expression, and thus restoring a normal cell phenotype. However, the promiscuous binding of miRNAs can provoke unwanted off-target effects, which are usually caused by high-dose single-miRNA treatments. Thus, it is desirable to develop miRNA therapeutics with increased specificity and efficacy. To achieve that, we propose the concept of miRNA cooperativity in order to exert synergistic repression on target genes, thus lowering the required total amount of miRNAs. We first review miRNA therapies in clinical application. Next, we summarize the knowledge on the molecular mechanism and biological function of miRNA cooperativity and discuss its application in cancer therapies. We then propose and discuss a systems biology approach to investigate miRNA cooperativity for the clinical setting. Altogether, we point out the potential of miRNA cooperativity to reduce off-target effects and to complement conventional, targeted, or immune-based therapies for cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available